Market Cap 2.59B
Revenue (ttm) 0.00
Net Income (ttm) -42.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,255,600
Avg Vol 2,200,904
Day's Range N/A - N/A
Shares Out 141.98M
Stochastic %K 57%
Beta 1.00
Analysts Strong Sell
Price Target $26.69

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 304 2499
Address:
195 Church Street, 16th Floor, New Haven, United States
PeterJPL
PeterJPL Aug. 2 at 7:18 PM
📌 5 Conditional Swing Setups — August 3–7 $APLD — 4.48/5 – AI-infrastructure continuation watch. PLTR, AMD, ANET and SOUN earnings can keep the data-center group active. $BBAI — 4.39/5 – Government and defense-AI sympathy setup. Needs strong PLTR read-through, contract headlines and sector volume. $OTLK — 4.31/5 – Post-approval LYTENAVA setup. Watching launch timing, reimbursement, financing needs and continuation versus sell-the-news pressure. $TRVI — 4.24/5 – Oppenheimer biotech event Aug. 4. Useful only if management provides meaningful new clinical or strategic commentary. $CAPR — 4.12/5 – High-risk regulatory-recovery trade after the negative AdCom vote. The Aug. 22 FDA date preserves volatility, but rejection risk remains elevated. These are more conditional than the top five; the catalyst still needs price and volume confirmation.
1 ¡ Reply
focafoca99
focafoca99 Jul. 28 at 11:54 AM
$TRVI participates in August biotech conferences, including Oppenheimer's Berkshires and Stifel's Summer Summit.
0 ¡ Reply
mrfridaynight
mrfridaynight Jul. 27 at 8:09 PM
$TRVI can’t believe more people aren’t here following the gem!!
2 ¡ Reply
mrfridaynight
mrfridaynight Jul. 24 at 8:07 PM
$TRVI lovely Friday afternoon rally!!!
1 ¡ Reply
Bfunk17
Bfunk17 Jul. 23 at 2:04 PM
$TRVI Terrific set-up for this gem.
1 ¡ Reply
notreload_ai
notreload_ai Jul. 21 at 5:18 PM
BMO Capital gives $TRVI an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis. https://notreload.xyz/xy/bmo-bullish-on-trevi-therapeutics-sees-first-in-class-potential-for-haduvio-in-ipf-cough/
0 ¡ Reply
Quantumup
Quantumup Jul. 20 at 9:58 PM
BMO Capital🏁 $TRVI and said -- We initiate coverage of Trevi Therapeutics with an Outperform rating and $36 target. $RHHBY VRNA - $MRK 𝑮̶𝑺̶𝑲̶ BMO Capital added—Our positive view is based on: 1) Haduvio's potentially first-in-class opportunity in IPF-related chronic cough, supported by clean Phase 2b CORAL data; 2) a differentiated central-plus-peripheral mechanism that may support best-in-class efficacy, 3) a coherent franchise strategy across IPF-CC, non-IPF ILD-CC, and refractory chronic cough; and 4) a defined late-stage development path, strong IP position, and balance sheet that support execution into pivotal data. Haduvio gives Trevi a credible path to lead in IPF-related chronic cough, a high-burden market with no approved therapies.
0 ¡ Reply
Bfunk17
Bfunk17 Jul. 20 at 5:36 PM
$TRVI The end is nearing and it will be a BO right around $30 or so. Looking good here.
1 ¡ Reply
anachartanalyst
anachartanalyst Jul. 20 at 2:02 PM
$TRVI https://anachart.com/wp-content/uploads/2026/07/1784556098_soc-img.jpg
0 ¡ Reply
Quantumup
Quantumup Jul. 20 at 11:17 AM
H.C. Wainwright⬆️ $TRVI to $24, reitd Buy/said: $GSK's decision not to progress camlipixant in refractory chronic cough, or RCC, was surprising given the earlier clinical data, but we view the announcement as a significant net positive for TRVI. VRNA - $MRK PFE Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2079163662070120861?s=20
0 ¡ Reply
Latest News on TRVI
Trevi Therapeutics rises 10.9%

2026-07-17T16:06:51.000Z - 17 days ago

Trevi Therapeutics rises 10.9%


Trevi Therapeutics rises 10.4%

2026-07-17T14:00:12.000Z - 17 days ago

Trevi Therapeutics rises 10.4%


Trevi Therapeutics management to meet with Cantor Fitzgerald

2026-07-13T14:15:20.000Z - 21 days ago

Trevi Therapeutics management to meet with Cantor Fitzgerald


Trevi Therapeutics Transcript: AGM 2026

Jun 3, 2026, 11:00 AM EDT - 2 months ago

Trevi Therapeutics Transcript: AGM 2026


Trevi Therapeutics Transcript: Investor Day 2026

May 7, 2026, 10:00 AM EDT - 3 months ago

Trevi Therapeutics Transcript: Investor Day 2026


Trevi Therapeutics Slides: FY 2026

May 7, 2026, 10:00 AM EDT - 3 months ago

Trevi Therapeutics Slides: FY 2026


Trevi Therapeutics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Trevi Therapeutics Earnings Call Transcript: Q1 2026


Trevi Therapeutics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Trevi Therapeutics Earnings release: Q1 2026


Trevi Therapeutics Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Trevi Therapeutics Quarterly report: Q1 2026


Trevi Therapeutics to Participate in Upcoming May Events

Apr 23, 2026, 4:05 PM EDT - 3 months ago

Trevi Therapeutics to Participate in Upcoming May Events


Trevi Therapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Trevi Therapeutics Proxy statement: Proxy filing


Trevi Therapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Trevi Therapeutics Proxy statement: Proxy filing


Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00

2026-04-17T10:32:43.000Z - 3 months ago

Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00


Trevi Therapeutics announces $150M common stock offering

2026-04-16T20:12:56.000Z - 3 months ago

Trevi Therapeutics announces $150M common stock offering


Trevi Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Trevi Therapeutics Proxy statement: Proxy filing


Trevi Therapeutics to Participate in Upcoming Events

Apr 1, 2026, 7:30 AM EDT - 4 months ago

Trevi Therapeutics to Participate in Upcoming Events


Trevi Therapeutics Earnings Call Transcript: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Trevi Therapeutics Earnings Call Transcript: Q4 2025


Trevi Therapeutics Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Trevi Therapeutics Annual report: Q4 2025


Trevi Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Trevi Therapeutics Earnings release: Q4 2025


Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)

2026-03-17T20:25:44.000Z - 4 months ago

Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)


Trevi Therapeutics to Participate in Upcoming March Conferences

Mar 2, 2026, 7:30 AM EST - 5 months ago

Trevi Therapeutics to Participate in Upcoming March Conferences


Trevi Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Trevi Therapeutics Earnings Call Transcript: Q3 2025


Trevi Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Trevi Therapeutics Quarterly report: Q3 2025


Trevi Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Trevi Therapeutics Earnings release: Q3 2025


Trevi Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings Call Transcript: Q2 2025


Trevi Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Quarterly report: Q2 2025


Trevi Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings release: Q2 2025


Trevi Therapeutics Transcript: Study Result

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Transcript: Study Result


Trevi Therapeutics Press release: Study Result

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Press release: Study Result


Trevi Therapeutics Slides: Study Result

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Slides: Study Result


Trevi Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings Call Transcript: Q1 2025


Trevi Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Quarterly report: Q1 2025


Trevi Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings release: Q1 2025


Trevi Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Trevi Therapeutics Proxy statement: Proxy Filing


Trevi Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Trevi Therapeutics Proxy statement: Proxy Filing


Trevi Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings Call Transcript: Q4 2024


Trevi Therapeutics Annual report: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Annual report: Q4 2024


Trevi Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings release: Q4 2024


Trevi Therapeutics Transcript: Study Result

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Transcript: Study Result


Trevi Therapeutics Press release: Study Result

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Press release: Study Result


Trevi Therapeutics Slides: Study Result

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Slides: Study Result


Trevi Therapeutics Transcript: Study Update

Dec 3, 2024, 5:00 PM EST - 1 year ago

Trevi Therapeutics Transcript: Study Update


Trevi Therapeutics Press release: Study Update

Dec 3, 2024, 5:00 PM EST - 1 year ago

Trevi Therapeutics Press release: Study Update


PeterJPL
PeterJPL Aug. 2 at 7:18 PM
📌 5 Conditional Swing Setups — August 3–7 $APLD — 4.48/5 – AI-infrastructure continuation watch. PLTR, AMD, ANET and SOUN earnings can keep the data-center group active. $BBAI — 4.39/5 – Government and defense-AI sympathy setup. Needs strong PLTR read-through, contract headlines and sector volume. $OTLK — 4.31/5 – Post-approval LYTENAVA setup. Watching launch timing, reimbursement, financing needs and continuation versus sell-the-news pressure. $TRVI — 4.24/5 – Oppenheimer biotech event Aug. 4. Useful only if management provides meaningful new clinical or strategic commentary. $CAPR — 4.12/5 – High-risk regulatory-recovery trade after the negative AdCom vote. The Aug. 22 FDA date preserves volatility, but rejection risk remains elevated. These are more conditional than the top five; the catalyst still needs price and volume confirmation.
1 ¡ Reply
focafoca99
focafoca99 Jul. 28 at 11:54 AM
$TRVI participates in August biotech conferences, including Oppenheimer's Berkshires and Stifel's Summer Summit.
0 ¡ Reply
mrfridaynight
mrfridaynight Jul. 27 at 8:09 PM
$TRVI can’t believe more people aren’t here following the gem!!
2 ¡ Reply
mrfridaynight
mrfridaynight Jul. 24 at 8:07 PM
$TRVI lovely Friday afternoon rally!!!
1 ¡ Reply
Bfunk17
Bfunk17 Jul. 23 at 2:04 PM
$TRVI Terrific set-up for this gem.
1 ¡ Reply
notreload_ai
notreload_ai Jul. 21 at 5:18 PM
BMO Capital gives $TRVI an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis. https://notreload.xyz/xy/bmo-bullish-on-trevi-therapeutics-sees-first-in-class-potential-for-haduvio-in-ipf-cough/
0 ¡ Reply
Quantumup
Quantumup Jul. 20 at 9:58 PM
BMO Capital🏁 $TRVI and said -- We initiate coverage of Trevi Therapeutics with an Outperform rating and $36 target. $RHHBY VRNA - $MRK 𝑮̶𝑺̶𝑲̶ BMO Capital added—Our positive view is based on: 1) Haduvio's potentially first-in-class opportunity in IPF-related chronic cough, supported by clean Phase 2b CORAL data; 2) a differentiated central-plus-peripheral mechanism that may support best-in-class efficacy, 3) a coherent franchise strategy across IPF-CC, non-IPF ILD-CC, and refractory chronic cough; and 4) a defined late-stage development path, strong IP position, and balance sheet that support execution into pivotal data. Haduvio gives Trevi a credible path to lead in IPF-related chronic cough, a high-burden market with no approved therapies.
0 ¡ Reply
Bfunk17
Bfunk17 Jul. 20 at 5:36 PM
$TRVI The end is nearing and it will be a BO right around $30 or so. Looking good here.
1 ¡ Reply
anachartanalyst
anachartanalyst Jul. 20 at 2:02 PM
$TRVI https://anachart.com/wp-content/uploads/2026/07/1784556098_soc-img.jpg
0 ¡ Reply
Quantumup
Quantumup Jul. 20 at 11:17 AM
H.C. Wainwright⬆️ $TRVI to $24, reitd Buy/said: $GSK's decision not to progress camlipixant in refractory chronic cough, or RCC, was surprising given the earlier clinical data, but we view the announcement as a significant net positive for TRVI. VRNA - $MRK PFE Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2079163662070120861?s=20
0 ¡ Reply
stockpicker63
stockpicker63 Jul. 18 at 4:50 AM
🚀 Weekly Results (July 13–17) Strong performance again this week. ⭐ Top Trades: $ZNTL +10.1% $CNMD +9.1% $DINO +8.8% $TRVI +8.7% $ANGO +7.4% 📊 Consistent gains across the board. Discipline. Strategy. Results.
0 ¡ Reply
herousa
herousa Jul. 17 at 8:47 PM
$TRVI Wow.. Good call .
0 ¡ Reply
topstockalerts
topstockalerts Jul. 17 at 6:09 PM
$TRVI what started as a small move is becoming more convincing.
0 ¡ Reply
letsgopeeps
letsgopeeps Jul. 17 at 5:30 PM
$TRVI I bought this in Feb.2022 for $.54 Unfortunately, not in a big number
1 ¡ Reply
prismmarketview
prismmarketview Jul. 17 at 4:03 PM
PRISM Mid-Day Movers: Fintech and Pharmaceuticals are Today’s Leaders. FiscalNote Holdings, Inc. (OTC: $NOTE) is ticking higher today, with the stock up about 16% to 0.10 from a prior level around 0.0859. Trevi Therapeutics, Inc. (NASDAQ: $TRVI ) is trading higher today, with the stock up about 10% to 19.165 from a prior close of 17.36. Other Notable Movers: Bitfarms (NASDAQ: $BITF) up 9% Alto Ingredients ($ALTO ) up 9% NUBURU Inc. ($BURU ) down 39% https://prismmarketview.com/prism-mid-day-movers-fintech-and-pharmaceuticals-are-todays-leaders/
0 ¡ Reply
Drew613
Drew613 Jul. 17 at 4:00 PM
$TRVI BO soon IMO!!! Very
1 ¡ Reply
jacksparo
jacksparo Jul. 17 at 3:43 PM
$TRVI Here you go all the proofs and well documented! Secured profits all the way up and kept what I can afford to lose …
0 ¡ Reply
jacksparo
jacksparo Jul. 17 at 3:40 PM
$TRVI Another one in my patience to pay biotech plays.. Started here back in 2024 ( it was also in my email list ) Up ⬆️ great here!
0 ¡ Reply
Faykar
Faykar Jul. 17 at 3:20 PM
$CNEY ENTERED top gainers list 🚀. $TRVI $SDOT $SLND
0 ¡ Reply
lecorb
lecorb Jul. 17 at 2:38 PM
0 ¡ Reply
Stock_Catcher
Stock_Catcher Jul. 17 at 2:23 PM
$TRVI Trend
0 ¡ Reply
BobMacDTruck
BobMacDTruck Jul. 17 at 1:47 PM
$TRVI $GSK now very interesting given their trial failed.
1 ¡ Reply